ESSA Pharma (EPIX)
(Delayed Data from NSDQ)
$6.09 USD
-0.07 (-1.14%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $6.00 -0.09 (-1.48%) 7:42 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
ESSA Pharma Inc. [EPIX]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for EPIX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Overall Phase 1/2 Continues to Support Benefit of Masofaniten. Cohort 4 not yet Mature. Key Phase 2 Trial Recently Initiated.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Initial Combo Efficacy Results Beat Benchmark and Support EPI-7386 Biology.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Yesterday, ESSA provided a corporate update and reported financial results for its fiscal third quarter.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Next Puzzle Piece Put in Place for EPI-7386 Thesis; Target to $32 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Positive Steps Begin for EPI-7386 with Encouraging First Clinical Look; Target Increased to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Window Into the Future? We Think So; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Excitement Continues to Grow Ahead of First EPI-7386 Data; Target Increased to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
EPI-7386 Should Continue to Drive Investor Excitement; PT Upped to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: ESSA Pharma Inc.
Industry: Medical - Drugs
ESSA Enters Critical New Phase; Strong Data Support Clinical Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J